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Summary
Background Temprano ANRS 12136 was a factorial 2 × 2 trial that assessed the benefits of early antiretroviral therapy 
(ART; ie, in patients who had not reached the CD4 cell count threshold used to recommend starting ART, as per the 
WHO guidelines that were the standard during the study period) and 6-month isoniazid preventive therapy (IPT) in 
HIV-infected adults in Côte d’Ivoire. Early ART and IPT were shown to independently reduce the risk of severe morbidity 
at 30 months. Here, we present the efficacy of IPT in reducing mortality from the long-term follow-up of Temprano.
Methods For Temprano, participants were randomly assigned to four groups (deferred ART, deferred ART plus IPT, 
early ART, or early ART plus IPT). Participants who completed the trial follow-up were invited to participate in a post-
trial phase. The primary post-trial phase endpoint was death, as analysed by the intention-to-treat principle. We used 
Cox proportional models to compare all-cause mortality between the IPT and no IPT strategies from inclusion in 
Temprano to the end of the follow-up period.
Findings Between March 18, 2008, and Jan 5, 2015, 2056 patients (mean baseline CD4 count 477 cells per µL) were 
followed up for 9404 patient-years (Temprano 4757; post-trial phase 4647). The median follow-up time was 4·9 years 
(IQR 3·3–5·8). 86 deaths were recorded (Temprano 47 deaths; post-trial phase 39 deaths), of which 34 were in patients 
randomly assigned IPT (6-year probability 4·1%, 95% CI 2·9–5·7) and 52 were in those randomly assigned no IPT 
(6·9%, 5·1–9·2). The hazard ratio of death in patients who had IPT compared with those who did not have IPT was 
0·63 (95% CI, 0·41 to 0·97) after adjusting for the ART strategy (early vs deferred), and 0·61 (0·39–0·94) after 
adjustment for the ART strategy, baseline CD4 cell count, and other key characteristics. There was no evidence for 
statistical interaction between IPT and ART (pinteraction=0·77) or between IPT and time (pinteraction=0·94) on mortality.
Interpretation In Côte d’Ivoire, where the incidence of tuberculosis was last reported as 159 per 100 000 people, 
6 months of IPT has a durable protective effect in reducing mortality in HIV-infected people, even in people with high 
CD4 cell counts and who have started ART.
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Introduction
Based on repeated evidence that isoniazid preventive 
therapy (IPT) decreases the risk of tuberculosis in HIV-
infected people, WHO has consistently recommended 
since 1993 that people living with HIV who are unlikely 
to have tuberculosis should receive at least 6 months of 
IPT.1 However, some countries still have not adopted IPT 
23 years later, and in most countries that have, IPT 
coverage is low.2,3 
Among the barriers to adopting IPT at country level are 
the absence of a common vision between HIV and 
tuberculosis programmes, and the fear that individuals 
who start IPT with unrecognised active tuberculosis 
might develop drug resistance.3–6 Most randomised 
controlled trials of IPT were done before the antiretroviral 
therapy (ART) era or in patients with CD4 counts of less 
than 500 per µL.7–10 Because ART also decreases the risk 
of tuberculosis,11–14 some physicians might prioritise 
successful ART and ensure immune recovery as early as 
possible, rather than implement IPT. Furthermore, all 
but one randomised controlled trials have shown the 
benefits of IPT in terms of tuberculosis reduction, not of 
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mortality.7–9 Some studies have suggested that these 
benefits might decrease after the treatment is stopped, 
leading to the consideration of extending treatment in 
settings with a high prevalence of tuberculosis.15–18 Finally, 
IPT efficacy in patients who had never had ART has been 
shown to be higher in patients with a positive tuberculin 
skin test (TST), who represent a minority of HIV-infected 
individuals who had never had ART.17,19,20
Between 2008 and 2015, we did a randomised controlled 
trial to assess the benefits of early ART and 6-month IPT 
in HIV-infected adults with high CD4 cell counts. The trial 
endpoint was severe morbidity at 30 months. The final 
analysis showed that early ART and IPT independently led 
to lower severe morbidity than did deferred ART and no 
IPT.12 After participants reached 30 months of follow-up in 
the trial, they continued to be followed up in a post-trial 
phase. Here we present the results of the analysis of the 
efficacy of IPT in reducing mortality at the end of the post-
trial phase. 
Methods
Study design and participants
Temprano ANRS 12136 was a 2 ×2 factorial randomised 
controlled trial done in Côte d’Ivoire. The trial design and 
results have been previously reported.12 Briefly, the 
inclusion criteria were HIV infection, age 18 years or 
older, CD4 count 800 cells per µL or lower, and no criteria 
for starting ART according to the most recent WHO 
guidelines (including the absence of active tuberculosis, 
as determined by using a clinical algorithm1,21). At the end 
of the 30-month follow-up period, we asked patients for a 
new written informed consent for participating in the 
post-trial phase (figure 1). The Temprano protocol 
(appendix), which included the post-trial phase, was 
approved by the Côte d’Ivoire National Ethics Committee 
for Health Research. 
Randomisation and masking
For the Temprano trial, participants were randomly 
assigned (1:1:1:1) to one of four groups: deferred ART 
(group 1), in which ART was deferred until WHO criteria 
for starting ART were met; deferred ART plus IPT 
(group 2), in which ART was deferred and 6-month IPT 
was prescribed; early ART (group 3), in which ART was 
started immediately; and early ART plus IPT (group 4), 
in which ART was started immediately and 6-month IPT 
was prescribed. Randomisation was done with a 
computer-generated, sequentially numbered, block 
randomisation list (block size 12), and was stratified by 
study clinic.
Procedures
After randomisation, all participants had a systematic 
chest radiograph and a series of blood tests including CD4 
cell count, plasma HIV-1 RNA, and serum amino-
transferase concentration. The first 50% of participants 
also had a QuantiFERON-TB Gold In-Tube test (QTF-GIT; 
Qiagen, Hilden, Germany). IPT consisted of 300 mg of 
isoniazid once per day, started at month 1 and stopped at 
month 7. Patients randomly assigned IPT, but who had 
images suggestive of active tuberculosis on their baseline 
chest radiograph, had elevated aminotransferases (more 
than 2·5 times the upper limit of normal), or developed 
signs suggestive of tuberculosis during the first month 
were not prescribed IPT. All participants were followed up 
for 30 months in the Temprano trial. 
The first Temprano participant completed 30 months of 
follow-up on Sept 13, 2010. From this date on, all patients 
who reached their 30-month visit were asked to continue 
being followed up in a post-trial phase until the last 
patient completed the trial-specified 30 months of follow-
up. The post-trial phase was started while the Temprano 
trial was still running, and the closing date was the same 
Research in context
Evidence before this study
We searched PubMed with search terms “tuberculosis” AND 
“prophylaxis” AND “HIV”, on Aug 1, 2016, for trials published in 
English. There were no date restrictions. Before this study, 
evidence from randomised trials suggested that 6–12 months 
of isoniazid preventive therapy (IPT) decreased the risk of 
tuberculosis in HIV-infected adults who were or were not on 
antiretroviral therapy (ART), and the risk of mortality in 
patients who were not on ART. However, no findings from 
randomised trials exist on the effect of IPT on risk of mortality 
in HIV-infected adults who had started ART. Furthermore, some 
trial results called into question the durability of the beneficial 
effect of IPT.
Added value of this study
Compared with previous trials that assessed the efficacy of IPT 
versus a placebo or no IPT, the median baseline CD4 count in 
our study was substantially higher and the follow-up time 
substantially longer. In our study, IPT led to a 37% reduction 
in mortality, and the efficacy of IPT in reducing mortality was 
independent of ART initiation and baseline CD4 cell count. 
The benefits of a 6-month IPT appeared to be sustained for 
up to 6 years of follow-up. These findings support the 
hypothesis that 6 months of IPT and ART could improve each 
other’s efficacy through complementary mechanisms.
Implications of all the available evidence
6 months of IPT has a durable protective effect in reducing 
all-cause mortality in people with HIV, even in people with high 
CD4 cell counts and who have started ART. IPT should be 
proposed to all adults who start ART at any CD4 cell count and 
have no evidence of active tuberculosis in sub-Saharan Africa.
See Online for appendix
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for both the trial and the post-trial phase. As a con-
sequence, the treatments received during the post-trial 
phase could not have been influenced by the final results 
of the trial.
Temprano and the post-trial phase had similar pro-
cedures. In the post-trial phase, as in Temprano, patients 
had quarterly visits to their care centre; CD4 cell count 
and plasma HIV-1 RNA were measured every 6 months; 
consultations, CD4 cell count, viral load, and antiretroviral 
drugs were free of charge; and patients who did not 
attend a trial visit were traced by experienced social 
workers. Patients followed up in the post-trial phase had 
to comply with the same rules regarding ART and IPT 
prescription as those who were followed up in the trial 
during the same calendar period. These rules were that 
patients assigned to the no IPT strategy never received 
IPT, neither during the trial nor during the post-trial 
phase; patients assigned to the deferred ART strategy 
started ART whenever they reached the most recent 
WHO criteria for starting ART, during the trial if these 
criteria were met 30 months after enrolment or earlier, or 
during the post-trial phase if these criteria were met later 
than 30 months after enrolment. Patients who did not 
reach these criteria before the closing date did not start 
ART, during the trial or during the post-trial phase. The 
most recent WHO criteria for starting ART were WHO 
2006 criteria between the beginning of the trial and 
November, 2009, WHO 2010 criteria between 
December, 2009, and July, 2013, and WHO 2013 criteria 
between August, 2013, and the trial and post-trial phase 
closing date. 
In case of a morbidity event in the Temprano trial phase, 
transportation for unscheduled visits, investigations, 
hospital admission, and non-antiretroviral drugs were 
free of charge. However, in the post-trial phase, patients 
had to pay for treatment, just as any other patient followed 
up in routine condition in the same care centre. 
Regardless of the similarities and differences between 
the trial and post-trial phases, individuals randomly 
assigned IPT and those randomly assigned no IPT had 
exactly the same assessments and clinical management 
(especially evaluation for active tuberculosis and ascer-
tainment of death) at the time of enrolment, during the 
trial phase, and during the post-trial phase.
Outcomes
The primary endpoint of the Temprano trial was severe 
morbidity, defined as a combination of all-cause deaths, 
AIDS diseases, non-AIDS malignancies, and non-AIDS 
invasive bacterial diseases, whereas it was all-cause 
mortality in the post-trial phase.
Statistical analysis
We refer to trial groups each time we show separate data 
for each of the four groups, and trial strategies whenever 
we show data combining patients assigned to IPT 
(groups 2 and 4), no IPT (groups 1 and 3), early ART 
(groups 3 and 4), and deferred ART (groups 1 and 2). 
In each group and strategy, we used the Kaplan-Meier 
method to estimate the cumulative probability of event 
occurrence. We estimated death rates by dividing the 
number of events by the cumulative person-time at risk. 
Figure 1: Study design of the Temprano trial and post-trial phase
ART=antiretroviral therapy. IPT=isoniazid preventive therapy.
Temprano trial 
primary outcome
Severe morbidity 
at 30 months
Post-trial phase
primary outcome
Death as of Jan 5, 2015 
Immediate ART
Immediate ART
Deferred ART
Deferred ARTIPT, 6 months
IPT, 6 months
No IPT
IPT
Temprano trial
Each participant was
followed up for 30 months
Post-trial phase
Each participant was followed up
until the last Temprano participant
reached 30 months of follow-up
Eligibility criteria
• CD4 count <800 cells
 per µL
• No WHO criteria for
 starting ART
• Informed consent
Randomisation
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The time at risk started at randomisation and ended on 
Jan 5, 2015. Follow-up data were censored when par-
ticipants died or were lost to follow-up. Patients were 
defined as lost to follow-up if they did not attend their 
last scheduled visit and if no further information on their 
vital status was available in the 6 months preceding the 
closing date of the database. 
Cox proportional hazards models were used to compare 
IPT strategies (IPT vs no IPT) with respect to mortality 
using the intention-to-treat approach. In the main 
analysis, we adjusted the hazard ratio (HR) for the other 
trial strategy (early ART vs deferred ART) and for the trial 
centre (as a random effect). In a secondary analysis, 
adjustment was also made for baseline CD4 cell count, to 
explore the effect of the extent of immunosuppression 
on the results; and for variables recognised as risk factors 
for mortality or tuberculosis, to address potential residual 
confounding effects of these variables. Finally, we 
compared IPT strategies with respect to loss-to-follow-
up, and death or loss to follow up, to examine the extent 
to which the primary results could be affected by attrition; 
we restricted the analyses to the sample of patients who 
had the QuantiFERON-TB Gold In-Tube test done at 
baseline, and stratified the analysis for the result of the 
test; and we used the per-protocol approach to compare 
IPT strategies with respect to mortality. In the per-
protocol analysis, we censored the follow-up of patients 
assigned to IPT: at 1 month for patients who did not start 
IPT; and on the date when IPT was discontinued for 
patients who started IPT, but discontinued it prematurely. 
The main analysis comparing IPT strategies with 
respect to mortality was predetermined in the Temprano 
trial protocol. The secondary and ancillary analyses are 
post-hoc analyses.
We tested interaction between strategies, and the 
assumption of the proportional hazards was examined. 
All reported p values were two-sided and were not 
adjusted for multiple testing. Statistical analyses were 
done with SAS software (version 9.3).
The Temprano trial is registered at ClinicalTrials.gov, 
number NCT00495651.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between March 18, 2008, and July 16, 2012, 2076 patients 
were randomly assigned to treatment groups; 20 (1%) 
were subsequently excluded and 2056 were included in 
the analyses (figure 2; appendix). The first 30-month visit 
was on Sept 13, 2010, and the last 30-month visit on 
Jan 5, 2015. All participants who were alive and followed 
up at the end of Temprano consented to participate in the 
extended follow-up (n=1951). 
Baseline and follow-up characteristics of the 2056 par-
ticipants according to IPT strategies (IPT and no IPT) are 
shown in table 1. Characteristics according to the 
four randomisation groups are shown in the appendix. 
Between March, 2008, and January, 2015, 2056 participants 
were followed up for 9404 person-years; 4757 person-
years during the trial and 4647 person-years during the 
post-trial phase. The median follow-up time was 4·9 years 
overall (IQR 3·3–5·8), 4·9 years (3·5–5·8) in the IPT 
strategy, and 4·8 years (3·3–5·8) in the no IPT strategy. 
Of 1030 patients assigned to the IPT strategy, 927 (90%) 
Figure 2: Trial profile
ART=antiretroviral therapy. IPT=isoniazid preventive therapy. *Patients were previously thought to have had dual 
infection with HIV-1 and HIV-2 on the basis of tests done locally. 
2962 screened for eligibility 
2076 randomly assigned
1038 allocated to no IPT 1038 allocated to IPT 
962 alive and followed up at the
 end of Temprano trial
75 lost to follow-up
23 died
864 alive and followed up at the
 end of the post-trial phase
1026 included in the 
 intention-to-treat analysis 
1030 included in the 
 intention-to-treat analysis
899 alive and followed up at the
 end of the post-trial phase
74 lost to follow-up
16 died
989 alive and followed up at the
 end of Temprano trial
886 not included
 451 declined to participate
 3 were pregnant
 48 had clinical indication to start ART
 261 had CD4 cell count below range for inclusion
 88 had CD4 cell count above range for inclusion
 2 were already receiving ART
 33 other reasons
12 excluded from follow-up 
 8 infected only with HIV-2 on
 HIV tests done at inclusion*
      3 HIV seronegative on tests
 done at inclusion (previously
 found to be HIV positive
 locally and followed up in
 HIV clinics for 76, 95,
  148 days before inclusion)
       1 had a history of combined
 ART that was discovered
 after inclusion
35 lost to follow-up
29 died
 8 excluded from follow-up
 7 infected only with HIV-2 on
 HIV tests done at inclusion*
 1 HIV seronegative on tests
 done at inclusion (previously
 found to be HIV positive
 locally and followed up in HIV
 clinics for 306 days before
 inclusion)
23 lost to follow-up
18 died
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started isoniazid, of whom 869 (94%) completed the 
6-month treatment (table 1). No patient assigned to the 
non-IPT strategy received IPT.
During follow-up, 86 deaths were recorded. The incidence 
of death was 0·7 per 100 person-years (95% CI 0·5–0·9) in 
the IPT group and 1·1 per 100 person-years (0·9–1·4) in the 
no IPT strategy, which ranged from 0·6 per 100 person-years 
(0·3–1·0) in group 4 (early ART plus IPT) to 1·3 per 
100 person-years (0·8–1·8) in group 1 (deferred ART, no 
IPT). The 6-year probability of death was 4·1% (95% CI 
2·9–5·7) in the IPT strategy group and 6·9% (5·1–9·2) in 
the no IPT strategy group (figure 3A), which ranged from 
3·2% (1·9–5·5) in group 4 (early ART plus IPT) to 7·0% 
(4·7–10·4) in group 1 (deferred ART, no IPT; figure 3B).
There was no statistical interaction with regard to 
mortality between the IPT and ART strategy (pinteraction=0·77), 
between IPT and time (pinteraction=0·94), or between ART 
and time (pinteraction=0·66; appendix). In the intention-to-
treat analysis, the HR of death for IPT compared with no 
IPT was 0·63 (95% CI 0·41–0·97) after adjusting for the 
ART strategy (early vs deferred) and the trial centre 
(table 2; main analysis); and 0·61 (0·39–0·94) after 
adjusting for the ART strategy, trial centre, baseline CD4 
cell count, sex, age, plasma HIV-1 RNA, haemoglobin, 
body-mass index, and past history of tuberculosis 
(secondary analysis addressing potential residual 
confounding effects). Other factors significantly associated 
with death were baseline CD4 count (<500 cells per µL vs 
≥500 cells per µL; HR 1·65 [95% CI 1·00–2·72], p=0·05), 
haemoglobin (<90 g/L vs ≥90 g/L; 2·65 [1·61–4·35], 
p=0·0001), and plasma HIV-1 RNA (<5 log10 copies per mL 
vs ≥5 log10 copies per mL; 0·59 [0·38–0·92], p=0·02). In 
the per-protocol analysis, the HR of death for IPT 
compared with no IPT was 0·54 (95% CI 0·33–0·87) after 
No IPT (n=1026) IPT (n=1030)
Baseline
Age (years) 35 (30–41) 35 (30–42)
Sex
Women 807 (79%) 807 (78%)
Men 219 (21%) 223 (22%)
Body-mass index (kg/m²) 22·6 (20·2–25·5) 22·3 (20·2–25·2)
WHO clinical stage
1 or 2 931 (91%) 927 (90%)
3 or 4 95 (9%) 103 (10%)
CD4 count (cells per μL) 465 (365–575) 464 (378–573)
CD4 count categories (cells per μL)
≥500 423 (41%) 426 (41%)
<500 603 (59%) 604 (59%)
Plasma HIV-1 RNA (log10 
copies per mL)
4·7 (4–5·2) 4·7 (4–5·3)
Plasma alanine 
aminotransferase >2·5 × ULN
4 (<1%) 6 (1%)
Haemoglobin <95 g/L 116 (11%) 122 (12%)
Past history of active 
tuberculosis
33 (3%) 28 (3%)
Positive IGRA for 
tuberculosis*
173/485 (36%) 164/482 (34%)
Immunovirological characteristics at 30 months
CD4 count (cells per μL) 421 (318–579) 435 (346–581)
Plasma HIV-1 RNA (log10 
copies per mL)
0 (0–3·5) 0 (0–3·5)
Follow-up
Follow-up time, overall 
(patient-years)
4636 4768
Temprano trial 2346 2413
Post-trial phase 2290 2355
Lost to follow-up, overall 110 (11%) 97 (9%)
Temprano trial 35 (3%) 23 (2%)
Post-trial phase 75 (7%) 74 (7%)
Deaths, overall 52 (5%) 34 (3%)
Temprano trial 29 (3%) 18 (2%)
Post-trial phase 23 (2%) 16 (2%)
(Table 1 continues in next column)
No IPT (n=1026) IPT (n=1030)
(Continued from previous column)
Ever started co-trimoxazole 988 (96%) 1002 (97%)
Ever started ART 901 (88%) 930 (90%)
First-line ART regimen
Tenofovir–emtricitabine 
plus efaviren
632 (70%) 652 (70%)
Tenofovir–emtricitabine 
plus LPV/r
200 (22%) 207 (22%)
Other† 69 (8%) 71 (8%)
Time spent on ART (years)
Temprano trial 1·8 (0·2–2·5) 1·9 (0·4–2·5)
Post-trial phase 2·0 (0·5–3·3) 2·2 (0·5–3·3)
Ever started IPT‡ 0 (0) 927 (90%)
Completed 6-month 
course§
0 (0) 869 (94%)
Data are n (%), n/N (%) or median (IQR). IPT=isoniazid preventive therapy. 
ULN=upper limit of normal. IGRA=interferon gamma release assay. 
ART=antiretroviral therapy. LPV/r=lopinavir/ritonavir. *Only the first 967 patients 
enrolled in Temprano (IPT: n=482; no IPT: n=485) were tested for tuberculosis 
with an IGRA (QuantiFERON-TB Gold In-Tube); indeterminate results 
were considered negative. †Other regimens were tenofovir–emtricitabine–
zidovudine (n=81), zidovudine–lamivudine–LPV/r (n=25), zidovudine–
lamivudine–efavirenz (n=3), zidovudine–lamivudine–nevirapine (n=3), 
didanosine–lamivudine–efavirenz (n=1), stavudine–lamivudine–efavirenz (n=1), 
stavudine–lamivudine–LPV/r (n=1), and lamivudine–abacavir–LPV/r (n=1). ‡The 
reasons for not starting IPT at 1 month were the presence of signs suggestive of 
tuberculosis on the chest radiograph obtained at baseline (n=16), the presence of 
clinical signs suggestive of tuberculosis at the 1-month visit (n=47), 
non-attendance at the 1-month visit (n=24), elevated aminotransferase 
concentrations at baseline (n=6), pregnancy (n=4), death before 1 month (n=1), 
and other reasons (n=5). §The reasons for stopping IPT prematurely were death 
from an unknown cause (n=1); discontinuation by patients for personal, 
non-medical reasons (n=22); discontinuation by physicians because of the 
presence in the patient of signs or symptoms suggestive of tuberculosis (n=10, 
of whom 3 were confirmed to have tuberculosis); pregnancy (n=13); and the 
following 12 adverse events: elevated aminotransferase concentration 
(two grade 2 events, two grade 3 events, and two grade 4 events), psychiatric 
side-effects (two grade 2 events and two grade 3 events), and pruritus 
(two grade 2 events); none of the episodes of elevated aminotransferase 
concentration led to death.
Table 1: Baseline and follow-up characteristics
Articles
e1085 www.thelancet.com/lancetgh   Vol 5   November 2017
adjusting for the ART strategy (early vs deferred) and the 
trial centre (main analysis); and 0·53 (0·32–0·86, p=0·01) 
after adjusting for the ART strategy, trial centre, baseline 
CD4 cell count, sex, age, plasma HIV-1 RNA, haemoglobin, 
body-mass index, and past history of tuberculosis 
(secondary analysis addressing potential residual 
confounding effects). Cause of death or probable cause of 
death was recorded in 25 deaths (13 in the IPT strategy 
group, 12 in the no IPT strategy group; appendix).
During follow-up, 207 patients were lost to follow-up 
(97 in the IPT strategy group, 110 in the no IPT strategy 
group), accounting for an overall rate of 2·2 per 
100 person-years (95% CI 1·9–2·5). The rate of loss to 
follow-up was 1·2 per 100 person-years during the trial 
phase (95% CI 0·9–1·5), and 3·2 per 100 person-years 
during the post-trial phase (2·7–3·7). The rate of loss to 
follow-up was 2·0 per 100 person-years in the IPT 
strategy group (1·6–2·4) versus 2·4 per 100 person-years 
in the no IPT strategy group (1·9–2·8). The 6-year 
probability of loss to follow-up was 14·7% (95% CI 
12·8–16·9) overall, 13·9 % (11·4–17·0) in the IPT strategy 
group, and 15·5% (12·8–18·7) in the no IPT strategy 
group. The 6-year probability of death or loss to follow-up 
was 17·4% (95% CI 14·7–20·6) in the IPT strategy group 
and 21·3% (95% CI 18·3–24·7) in the no IPT strategy 
group (appendix). 
There was no statistical interaction between IPT and 
ART with regard to mortality or loss to follow-up 
(pinteraction=0·50). The HR of death or loss to follow-up for 
IPT compared with no IPT was 0·78 (95% CI 0·62–0·98) 
after adjusting for the ART strategy (early vs deferred) 
and the trial centre (table 2), and 0·77 (0·61–0·97) after 
adjusting for the ART strategy, trial centre, baseline CD4 
cell count, sex, age, plasma HIV-1 RNA, haemoglobin, 
body-mass index, and past history of tuberculosis.
Of the 967 patients who had a QTF-GIT test at baseline 
(482 in the IPT strategy group, 485 in the no IPT strategy 
group), the test was positive in 337 patients (IPT 164, no 
IPT 173), negative in 597 (IPT 306, no IPT 291), and 
indeterminate in 33 (IPT 12, no IPT 21). In patients with 
baseline CD4 counts of less than 500 cells per µL, 
269 (35%) patients had positive tests, 480 (62%) had 
negative tests, and 27 (3%) had indeterminate tests 
versus 68 (36%) who had positive tests, 117 (61%) who 
had negative tests, and six (3%) who had indeterminate 
tests, in patients with baseline CD4 counts of 500 cells 
per µL or higher (p=0·95). In patients aged 50 years or 
older, 30 (35%) patients had positive tests, 50 (58%) had 
negative tests, and six (7%) had indeterminate tests 
versus 307 (35%) who had positive tests, 547 (62%) who 
had negative tests, and 27 (3%) who had indeterminate 
tests in those younger than 50 years (p=0·16). 
The 6-year probability of death was 3·1% (95% CI 
1·3–7·3) in the IPT strategy group and 5·2% (2·6–10·4) in 
the no IPT strategy group in patients with positive baseline 
QTF-GIT test (figure 4A); and 5·2% (3·2–8·3) in the IPT 
strategy and 8·5% (5·7–12·4) in the no IPT strategy group 
in those with negative QTF-GIT test (figure 4B).
There was no statistical interaction between the result of 
the QTF-GIT test at baseline and the IPT strategy with 
regard to mortality (pinteraction=0·96). When stratifying the 
analysis by baseline QTF-GIT test results, the adjusted 
HR of death for IPT compared with no IPT was 0·61 
(95% CI 0·20–1·86) in patients with positive QTF-GIT 
and 0·63 (0·33–1·18) in those with negative or 
indeterminate QTF-GIT. 
Discussion
Our findings from the long-term follow-up of the 
Temprano trial showed that IPT led to a 37% reduction in 
mortality, which accounted for an absolute reduction of 
–2·79% in the probability of death 6 years after 
randomisation. To our knowledge, this is the first evidence 
Figure 3: Kaplan-Meier curves of probability of death in all patients
(A) By IPT strategy (n=2056). (B) By randomisation group (n=2056). IPT=isoniazid preventive therapy. 
ART=antiretroviral therapy.
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from a randomised trial showing that IPT decreases 
mortality in HIV-infected adults with high CD4 cell counts 
and in the ART era. The only previous randomised trial9 
that showed a mortality reduction with IPT was done in 
Haiti in the late 1980s, which was in the pre-ART era and 
done in patients whose CD4 cell counts were unknown. 
We also found no statistical evidence for an interaction 
between IPT and ART with regard to mortality. IPT and 
ART had an additive effect, with the maximal benefit in 
patients who had both therapies, which suggests that 
receiving both treatments was a better option than 
receiving either therapy alone. In a placebo-controlled 
trial10 done in South Africa in HIV-infected adults receiving 
ART, who had a median of 216 CD4 cells per µL at baseline, 
and were followed up for a mean of 2·5 years, IPT 
decreased the risk of active tuberculosis by 37%. Our 
finding that IPT decreases mortality inde pendently of 
CD4 cell count in HIV-infected adults who had a median 
baseline CD4 count of 465 cells per µL and followed up for 
a mean of 4·6 years adds to evidence that IPT should be 
given in patients on ART who have any CD4 cell count. 
Apart from these primary conclusions, our data also 
shed light on two important issues: the durability of IPT’s 
beneficial effect and the effect of IPT in patients with 
documented latent tuberculosis infection compared with 
other patients. 
In the 1990s, randomised controlled trials of IPT in 
patients who had never had ART reached contrasting 
conclusions on the sustainability of the effect of IPT. 
These findings led to the question of whether continuous 
IPT was needed to ensure long-term protection in 
settings with a high incidence of tuberculosis.7–9,15,16 One 
randomised con trolled trial17 in Botswana concluded that 
36 months of IPT was more effective than 6 months, 
whereas the other trial22 in South Africa concluded that 
continuous IPT taken for a mean duration of 3·9 years 
was not superior to 6 months of treatment. However, the 
findings from the trial in South Africa did show benefit 
of continuous IPT in the per-protocol analysis. Both of 
these trials therefore support continued protection while 
patients are on IPT.
In our study, the follow-up time was substantially longer 
than that in the previous placebo controlled trials of 
IPT,7–10,15,16 and the benefits of 6 months of IPT appeared to 
be sustainable up to 6 years after the intervention, as 
shown by the Kaplan-Meier probabilities at 6 years and the 
absence of interaction between IPT and time with regard to 
mortality. These findings are consistent with those of a 
study23 in Brazil, which showed long-term durability of IPT 
in a setting where ART is widely available. These study 
findings support the hypothesis that 6 months of IPT and 
ART could improve each other’s efficacy through 
complementary mechanisms; while the IPT can cure latent 
Mycobacterium tuberculosis infection and prevent new 
infections during the course of the treatment, ART leads to 
immune recovery that decreases the risk of both new 
tuberculosis infection and tuberculosis reactivation in the 
longer term.24 That said, when interpreting the efficacy 
over time of a 6-month course of IPT versus IPT of longer 
duration, it is important to note the background risk of 
infection in the area. The incidence of tuberculosis in 
South Africa, Botswana, and Côte d’Ivoire was last re-
ported in 2014 as 834 per 100 000 people, 356 per 
100 000 people, and 159 per 100 000 people, respectively.25 
Previous randomised controlled trials7–9,15,16,20 of IPT in 
patients who were not on ART suggested that the efficacy 
of IPT was higher in patients with a positive TST. A 
2010 meta-analysis20 suggested that IPT significantly 
decreases the risk of active tuberculosis and the risk of 
death in TST-positive, but not TST-negative, HIV-infected 
people. In the trial10 of IPT on ART in South Africa, 
however, subgroup analysis stratified by TST or interferon 
gamma release assay (IGRA) results showed that the 
protective effect of IPT against tuberculosis was 
statistically significant in patients with a negative TST or 
a negative IGRA and not significant in those with a 
positive TST or a positive IGRA. Importantly, the HRs of 
tuberculosis in patients receiving IPT versus those 
receiving placebo were similar in subgroups of patients 
with positive or negative IGRA results. The fact that one 
was significant and the other not was probably because 
the study was not powered for this ancillary analysis. Our 
own findings were consistent with this; we also found 
similar HRs of death in the IPT versus no IPT strategies 
in subgroup analyses of patients with positive or negative 
QTF-GIT results. The shape of the mortality curves in 
N Death Death or loss to follow-up
n Rate (per 
100 person-years)
aHR (95% CI) p value n Rate (per 
100 person-years)
aHR (95% CI) p value
IPT strategy
No IPT 1026 52 1·12 ·· ·· 162 3·49 ·· ··
IPT 1030 34 0·71 0·63 (0·41–0·97) 0·04 131 2·75 0·78 (0·62–0·98) 0·03
ART strategy
Deferred ART 1023 49 1·05 ·· ·· 165 3·54 ·· ··
Immediate ART 1033 37 0·78 0·74 (0·48–1·13) 0·17 128 2·70 0·76 (0·60–0·95) 0·02
Hazard ratios were adjusted for study centre and for the other strategy. aHR=adjusted hazard ratio. IPT=isoniazid preventive therapy. ART=antiretroviral therapy. 
Table 2: Rates and hazard ratios of death and death or loss to follow-up
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both subgroups in our study suggests that the efficacy of 
IPT was maximal during the early follow-up in patients 
with positive QTF-GIT test, and during the late follow-up 
in those with negative QTF-GIT test. Finally, in our study, 
overall mortality rates appeared to be lower in patients 
who had a positive QTF-GIT test than in those with a 
negative test, despite similar distributions of CD4 cell 
count categories at baseline. This finding suggests that 
the test might be a measure of immune competence with 
possible prognostic value, a hypothesis that should be 
explored further.
Our study has several limitations. First, although we 
reported severe morbidity events at 30 months in the 
Temprano study,12 we did not report long-term morbidity 
data in this report of the long-term follow-up. During the 
Temprano trial phase, the event documentation 
committee used standardised criteria to validate and 
classify all severe morbidity events. These criteria were a 
combination of clinical definitions and laboratory and 
radiological test results. Some clinical definitions 
included evolution under standardised care and 
treatment.12 During the post-trial phase, participants had 
to pay for tests other than routine ART monitoring tests, 
and for care and treatment other than ART. Therefore, 
we did not document morbidity events during the post-
trial phase, and focused efforts on recording mortality. 
18 papers previously reported the results of primary IPT 
trials.7–10,12,15–18,22,26–33 All studies had all-cause mortality as a 
primary or secondary outcome, and none chose 
tuberculosis mortality. Causes of death were reported in 
only four papers. In these four papers, death of unknown 
cause was frequent.10,17,30,31 All-cause mortality is a better 
primary outcome than tuberculosis mortality for an IPT 
trial. Even if it were feasible to document all causes of 
death, an intervention that would decrease disease-
specific mortality, but that did not decrease all-cause 
mortality, would not have the same public health impact 
as one that decreases all-cause mortality. Further-
 more, all-cause mortality is much less subject to mis-
classification bias than disease-specific mortality. Finally, 
causes of mortality are very difficult to document in HIV 
trials done in low-resource settings because many 
patients die at home. Even for individuals who die in 
hospital settings, fewer facilities are available to 
document morbidity compared with hospital settings in 
high-resource countries. Therefore, the causes of death 
that we report must be considered with caution.
Second, open-label trials are more susceptible to bias 
than blinded trials because knowledge of treatment 
allocation can affect post-randomised treatment de-
cisions and reporting of outcomes. In our study, patients 
in the two strategy groups had similar rates of loss to 
follow-up, similar percentages of patients on ART over 
time, similar time spent on ART, and similar percentages 
of patients on co-trimoxazole over time. These patients 
also had similar CD4 cell counts and viral load 
distributions at the end of the Temprano trial phase, 
when they entered the post-trial phase. These findings 
suggest that there was no differ ential care management, 
although they do not prove it. Additionally, 10% of 
patients were lost to follow-up in both groups. Among 
these patients lost to follow-up, undocumented deaths 
could have been more frequent in patients randomly 
assigned IPT compared with those randomly assigned 
no IPT. Because undocumented death could only occur 
in patients lost to follow-up, and because the rates of loss 
to follow-up were similar between strategies and even 
slightly higher in the no IPT group, we do not believe 
that the risk of under-reported death rates in IPT 
compared with the no IPT group was high, but we cannot 
completely rule out this risk. In all cases, the evidence 
would have been stronger if we had used a placebo.
Third, tests for interaction reject the hypothesis of no 
interaction if there is strong evidence of an interaction. 
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Figure 4: Kaplan-Meier curves of probability of death in patients with a QuantiFERON-TB Gold In-Tube test 
result
(A) Positive test (n=337). (B) Negative test (n=630). IPT=isoniazid preventive therapy.
Articles
www.thelancet.com/lancetgh   Vol 5   November 2017 e1088
Failure to reject does not prove that the effect of ART and 
IPT are independent. This fact is important in the 
interpretation of our results, and the reason for which it 
is more accurate to say that there was no evidence for an 
interaction between ART and IPT rather than that there 
was evidence for the effect of both interventions being 
completely independent. 
In conclusion, in these African HIV-infected adults with 
high CD4 cell counts, 6 months of IPT led to a 
37% decrease in mortality, independently of baseline 
CD4 cell count and with no significant evidence for an 
interaction between IPT and ART. 6 months of IPT should 
be proposed to all adults who start ART at any CD4 cell 
count and have no evidence of active tuberculosis in sub-
Saharan Africa, regardless of IGRA or TST status.34,35
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